End-of-day quote
Shenzhen S.E.
03:30:00 24/06/2024 am IST
|
5-day change
|
1st Jan Change
|
70.53
CNY
|
-1.01%
|
|
-5.58%
|
-39.25%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
29,964
|
72,546
|
1,11,228
|
52,704
|
41,387
|
23,636
|
-
|
-
|
Enterprise Value (EV)
1 |
29,964
|
72,546
|
1,05,428
|
47,553
|
34,424
|
17,343
|
17,064
|
16,233
|
P/E ratio
|
54
x
|
97.1
x
|
99.1
x
|
16.4
x
|
18.5
x
|
19
x
|
14.8
x
|
12.7
x
|
Yield
|
0.39%
|
0.2%
|
0.18%
|
1.22%
|
1.55%
|
1.06%
|
1.22%
|
1.45%
|
Capitalization / Revenue
|
12.2
x
|
23
x
|
24
x
|
5.15
x
|
5.29
x
|
3.69
x
|
3.19
x
|
2.7
x
|
EV / Revenue
|
12.2
x
|
23
x
|
22.8
x
|
4.65
x
|
4.4
x
|
2.71
x
|
2.3
x
|
1.85
x
|
EV / EBITDA
|
40
x
|
74.3
x
|
83.1
x
|
13.6
x
|
11.3
x
|
10.8
x
|
8.19
x
|
6.15
x
|
EV / FCF
|
-
|
-163
x
|
-68.2
x
|
41.8
x
|
14.9
x
|
-251
x
|
21.3
x
|
16.5
x
|
FCF Yield
|
-
|
-0.61%
|
-1.47%
|
2.39%
|
6.7%
|
-0.4%
|
4.68%
|
6.08%
|
Price to Book
|
9.84
x
|
12.1
x
|
9.07
x
|
3.5
x
|
2.46
x
|
1.4
x
|
1.31
x
|
1.18
x
|
Nbr of stocks (in thousands)
|
3,23,935
|
3,39,521
|
3,68,307
|
3,64,755
|
3,64,426
|
3,51,942
|
-
|
-
|
Reference price
2 |
92.50
|
213.7
|
310.7
|
148.0
|
116.1
|
68.97
|
68.97
|
68.97
|
Announcement Date
|
28/02/20
|
15/04/21
|
30/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,460
|
3,150
|
4,632
|
10,230
|
7,825
|
6,405
|
7,408
|
8,767
|
EBITDA
1 |
748.6
|
976.8
|
1,269
|
3,498
|
3,058
|
1,600
|
2,084
|
2,638
|
EBIT
1 |
623.7
|
816.9
|
1,068
|
3,136
|
2,571
|
1,343
|
1,763
|
2,211
|
Operating Margin
|
25.35%
|
25.94%
|
23.05%
|
30.65%
|
32.85%
|
20.97%
|
23.79%
|
25.22%
|
Earnings before Tax (EBT)
1 |
623.6
|
814.4
|
1,193
|
3,725
|
2,557
|
1,411
|
1,814
|
2,272
|
Net income
1 |
553.9
|
722.1
|
1,069
|
3,302
|
2,269
|
1,327
|
1,705
|
2,006
|
Net margin
|
22.51%
|
22.93%
|
23.08%
|
32.27%
|
28.99%
|
20.72%
|
23.01%
|
22.88%
|
EPS
2 |
1.714
|
2.200
|
3.136
|
9.000
|
6.260
|
3.625
|
4.660
|
5.426
|
Free Cash Flow
1 |
-
|
-445.6
|
-1,547
|
1,136
|
2,308
|
-69
|
799.2
|
986.5
|
FCF margin
|
-
|
-14.15%
|
-33.39%
|
11.11%
|
29.5%
|
-1.08%
|
10.79%
|
11.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
32.49%
|
75.49%
|
-
|
38.35%
|
37.4%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
34.42%
|
101.73%
|
-
|
46.89%
|
49.19%
|
Dividend per Share
2 |
0.3571
|
0.4286
|
0.5714
|
1.800
|
1.800
|
0.7332
|
0.8411
|
0.9995
|
Announcement Date
|
28/02/20
|
15/04/21
|
30/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S2
|
2022 S1
|
2022 Q3
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2,879
|
5,034
|
2,770
|
5,198
|
2,249
|
2,350
|
4,596
|
1,762
|
1,481
|
3,186
|
1,400
|
1,451
|
2,815
|
1,595
|
1,845
|
3,441
|
2,203
|
2,324
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
710.6
|
1,699
|
-
|
1,464
|
-
|
952
|
1,670
|
559.8
|
81.2
|
565.4
|
-
|
266.1
|
447.5
|
212.8
|
275.3
|
488
|
-
|
-
|
Operating Margin
|
24.69%
|
33.74%
|
-
|
28.17%
|
-
|
40.52%
|
36.35%
|
31.78%
|
5.48%
|
17.75%
|
-
|
18.33%
|
15.9%
|
13.34%
|
14.92%
|
14.18%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
559.6
|
69.01
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
980.8
|
-
|
-
|
-
|
-
|
523.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
35.41%
|
-
|
-
|
-
|
-
|
29.73%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
1.720
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/22
|
25/08/22
|
27/10/22
|
30/03/23
|
28/04/23
|
29/08/23
|
29/08/23
|
30/10/23
|
28/03/24
|
28/03/24
|
25/04/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
5,800
|
5,151
|
6,963
|
6,293
|
6,572
|
7,403
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-446
|
-1,547
|
1,136
|
2,308
|
-69
|
799
|
986
|
ROE (net income / shareholders' equity)
|
19.9%
|
18.2%
|
12.1%
|
23.4%
|
13.7%
|
7.21%
|
8.55%
|
9.46%
|
ROA (Net income/ Total Assets)
|
16%
|
13.2%
|
10.1%
|
19.8%
|
11.9%
|
4.12%
|
6.8%
|
8.36%
|
Assets
1 |
3,472
|
5,458
|
10,635
|
16,698
|
19,003
|
32,182
|
25,069
|
23,982
|
Book Value Per Share
2 |
9.400
|
17.70
|
34.20
|
42.30
|
47.30
|
49.20
|
52.80
|
58.50
|
Cash Flow per Share
2 |
1.850
|
1.680
|
3.310
|
8.960
|
9.600
|
4.850
|
4.260
|
5.720
|
Capex
1 |
511
|
1,015
|
1,660
|
2,151
|
1,242
|
1,209
|
1,278
|
1,363
|
Capex / Sales
|
20.76%
|
32.22%
|
35.83%
|
21.02%
|
15.87%
|
18.88%
|
17.26%
|
15.55%
|
Announcement Date
|
28/02/20
|
15/04/21
|
30/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
68.97
CNY Average target price
99.42
CNY Spread / Average Target +44.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -39.25% | 3.25B | | +55.19% | 815B | | +47.26% | 654B | | -6.09% | 354B | | +21.92% | 337B | | +18.40% | 247B | | +3.64% | 229B | | +12.98% | 219B | | +10.86% | 171B | | -2.78% | 159B |
Other Pharmaceuticals
|